These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 12063825)

  • 1. Immunotherapy for pancreatic cancer: current concepts.
    Kaufman HL; Di Vito J; Hörig H
    Hematol Oncol Clin North Am; 2002 Feb; 16(1):159-97, viii. PubMed ID: 12063825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Active immunotherapy of prostate cancer with a focus on dendritic cells].
    Thomas-Kaskel AK; Veelken H
    Actas Urol Esp; 2007 Jun; 31(6):668-79. PubMed ID: 17896564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of metastasis.
    Dallal RM; Lotze MT
    Surg Oncol Clin N Am; 2001 Apr; 10(2):433-47, xi. PubMed ID: 11382596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
    Amedei A; Niccolai E; Prisco D
    Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovative treatments for pancreatic cancer.
    Lieberman SM; Hörig H; Kaufman HL
    Surg Clin North Am; 2001 Jun; 81(3):715-39. PubMed ID: 11459285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunotherapy: new insights].
    Geissler M; Weth R
    Praxis (Bern 1994); 2002 Dec; 91(51-52):2236-46. PubMed ID: 12564040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer vaccines: an update.
    Hipp JD; Hipp JA; Lyday BW; Minev BR
    In Vivo; 2000; 14(5):571-85. PubMed ID: 11125541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
    Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
    Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Algenpantucel-L immunotherapy in pancreatic adenocarcinoma.
    Coveler AL; Rossi GR; Vahanian NN; Link C; Chiorean EG
    Immunotherapy; 2016 Feb; 8(2):117-25. PubMed ID: 26787078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for immunotherapy of cancer.
    Melief CJ; Toes RE; Medema JP; van der Burg SH; Ossendorp F; Offringa R
    Adv Immunol; 2000; 75():235-82. PubMed ID: 10879286
    [No Abstract]   [Full Text] [Related]  

  • 11. Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.
    Kinkead HL; Hopkins A; Lutz E; Wu AA; Yarchoan M; Cruz K; Woolman S; Vithayathil T; Glickman LH; Ndubaku CO; McWhirter SM; Dubensky TW; Armstrong TD; Jaffee EM; Zaidi N
    JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells.
    Stift A; Friedl J; Dubsky P; Bachleitner-Hofmann T; Benkoe T; Brostjan C; Jakesz R; Gnant M
    Int J Oncol; 2003 Mar; 22(3):651-6. PubMed ID: 12579320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential targets for pancreatic cancer immunotherapeutics.
    Dodson LF; Hawkins WG; Goedegebuure P
    Immunotherapy; 2011 Apr; 3(4):517-37. PubMed ID: 21463193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell epitope peptide vaccines.
    Elsawa SF; Rodeberg DA; Celis E
    Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutated Ras peptides as vaccines in immunotherapy of cancer.
    Gjertsen MK; Gaudernack G
    Vox Sang; 1998; 74 Suppl 2():489-95. PubMed ID: 9704487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients.
    Staib L; Birebent B; Somasundaram R; Purev E; Braumüller H; Leeser C; Küttner N; Li W; Zhu D; Diao J; Wunner W; Speicher D; Beger HG; Song H; Herlyn D
    Int J Cancer; 2001 Apr; 92(1):79-87. PubMed ID: 11279610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapy: moving forward with peptide T cell vaccines.
    Kumai T; Fan A; Harabuchi Y; Celis E
    Curr Opin Immunol; 2017 Aug; 47():57-63. PubMed ID: 28734176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccines as treatment strategies for relapsed prostate cancer: approaches for induction of immunity.
    Slovin SF
    Hematol Oncol Clin North Am; 2001 Jun; 15(3):477-96. PubMed ID: 11525292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.